Standard precautions are taken in vaccine trials to ensure that the experimental vaccine does not have a serious effect on the people involved in the trial.
However, despite all precautions, in September the pharmaceutical company AstraZeneca suspended the trial of the coronavirus vaccine, dubbed the Oxford Vaccine, due to an unknown disease in the volunteer.
Details of the volunteer’s illness were not released but the vaccine trial was resumed after a week-long hiatus.
Leading multinational pharmaceutical company Johnson & Johnson suspended the trial phase of the vaccine on October 12 due to a negative reaction from its Corona vaccine volunteers.
According to the company, the trial of the vaccine was stopped after some volunteers complained of an unknown disease.
Now a volunteer has died during a trial of the experimental Corona virus vaccine of the Brazilian pharmaceutical company AstraZeneca.
During the trial, the volunteer’s death was announced by the Brazilian health agency Envisa.
However, the trial organizers said that despite the death of the volunteer, there was no reason to stop the trial, which indicates that his death was not linked to the vaccine.
The volunteer’s death was reported on Monday (October 19th), but the International Evaluation and Security Committee, which oversees the trial, recommended that the trial be continued, CNN reported.
It is not clear if the volunteer was vaccinated or given a placebo shot during the trial, but Envisa said no further information would be released due to medical privacy reasons.
Oxford University, on the other hand, said in an email to CNN that “all major medical events, whether participants in the control group or the Code-19 vaccine group, were independently reviewed.” is going’.
The University of Oxford said that after a careful review of the case in Brazil, there were no reservations about the clinical trial and that the Brazilian Authority had recommended that the trial be continued with an independent review.
Read more: Oxford University vaccine trial resumes after a week-long hiatus
D and the institute, which handles clinical trials in Rio, said 8,000 people were given a placebo or vaccine during the trial.
The institute said in a statement that “according to the analysis of the data collected so far, there are no doubts about the safety of the research and therefore the trial has been allowed to continue.”
A spokeswoman for AstraZeneca declined to comment, saying “we cannot comment on individual cases due to medical privacy and the law.”